{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:04:37Z","timestamp":1747109077744,"version":"3.40.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,12]]},"DOI":"10.7759\/cureus.83966","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:40:36Z","timestamp":1747064436000},"source":"Crossref","is-referenced-by-count":0,"title":["Prolonged Serotonergic Symptoms in a Pediatric Patient: Suspected Interaction Between Prescription Medications and Kava Supplement"],"prefix":"10.7759","author":[{"given":"Tamas R","family":"Peredy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E","family":"Samai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2022.2140292","article-title":"Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects","volume":"49","author":"Pont-Fernandez S","year":"2023","unstructured":"Pont-Fernandez S, Kheyfets M, Rogers JM, Smith KE, Epstein DH. Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects. Am J Drug Alcohol Abuse. 2023, 49:85-96. 10.1080\/00952990.2022.2140292","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2010.522554","article-title":"Kava: a comprehensive review of efficacy, safety, and psychopharmacology","volume":"45","author":"Sarris J","year":"2011","unstructured":"Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011, 45:27-35. 10.3109\/00048674.2010.522554","journal-title":"Aust N Z J Psychiatry"},{"key":"ref3","article-title":"Kava, an overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb","volume":"154","author":"Singh YN","year":"1997","unstructured":"Singh YN, Blumenthal M. Kava, an overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb. HerbalGram. 1997, 154:33-55.","journal-title":"HerbalGram"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003383","article-title":"Kava extract versus placebo for treating anxiety","volume":"2003","author":"Pittler MH","year":"2003","unstructured":"Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev. 2003, 2003:CD003383. 10.1002\/14651858.CD003383","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1081\/clt-120019123","article-title":"Acute hepatitis induced by kava kava","volume":"41","author":"Humberston CL","year":"2003","unstructured":"Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol. 2003, 41:109-13. 10.1081\/clt-120019123","journal-title":"J Toxicol Clin Toxicol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-1-200107030-00036","article-title":"Kava hepatotoxicity","volume":"135","author":"Russmann S","year":"2001","unstructured":"Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med. 2001, 135:68-9. 10.7326\/0003-4819-135-1-200107030-00036","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.11.1153","article-title":"Inhibition of human cytochrome P450 activities by kava extract and kavalactones","volume":"30","author":"Mathews JM","year":"2002","unstructured":"Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos. 2002, 30:1153-7. 10.1124\/dmd.30.11.1153","journal-title":"Drug Metab Dispos"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach H","year":"1991","unstructured":"Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991, 148:705-13. 10.1176\/ajp.148.6.705","journal-title":"Am J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley EJ","year":"2003","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003, 96:635-42. 10.1093\/qjmed\/hcg109","journal-title":"QJM"},{"key":"ref10","article-title":"Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient","author":"Chai P","year":"2017","unstructured":"Chai P, Boyer E. Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient. Brent J (ed): Springer, New York, NY; 2017."},{"key":"ref11","unstructured":"Cymbalta (duloxetine). (2017). Accessed. February 24, 2025: https:\/\/pi.lilly.com\/ca\/cymbalta-ca-pm.pdf."},{"key":"ref12","unstructured":"Effexor (venlafaxine). (2018). Accessed. February 24, 2025: http:\/\/labeling.pfizer.com\/showlabeling.aspx?ID=100#S12.3."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.01.009","article-title":"In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4\/5 phenotypes","volume":"77","author":"Gurley BJ","year":"2005","unstructured":"Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4\/5 phenotypes. Clin Pharmacol Ther. 2005, 77:415-26. 10.1016\/j.clpt.2005.01.009","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200600300","article-title":"Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea","volume":"52","author":"Gurley BJ","year":"2008","unstructured":"Gurley BJ, Swain A, Hubbard MA, et al.. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res. 2008, 52:755-63. 10.1002\/mnfr.200600300","journal-title":"Mol Nutr Food Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/a-1008-9491","article-title":"Monoamine oxidase inhibition by kavalactones from kava (Piper methysticum)","volume":"85","author":"Prinsloo D","year":"2019","unstructured":"Prinsloo D, van Dyk S, Petzer A, Petzer JP. Monoamine oxidase inhibition by kavalactones from kava (Piper methysticum). Planta Med. 2019, 85:1136-42. 10.1055\/a-1008-9491","journal-title":"Planta Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcme.2021.07.002","article-title":"Ex\u00a0vivo and in\u00a0vitro inhibitory potential of kava extract on monoamine oxidase B activity in mice","volume":"12","author":"Krum BN","year":"2022","unstructured":"Krum BN, de Freitas CM, Busanello A, Schaffer LF, Fachinetto R. Ex\u00a0vivo and in\u00a0vitro inhibitory potential of kava extract on monoamine oxidase B activity in mice. J Tradit Complement Med. 2022, 12:115-22. 10.1016\/j.jtcme.2021.07.002","journal-title":"J Tradit Complement Med"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.4172\/Neuropsychiatry.1000117","article-title":"MTHFR gene polymorphism positive treatment-resistant depression: prevalence and treatment recommendations","volume":"6","author":"Duprey RP","year":"2016","unstructured":"Duprey RP. MTHFR gene polymorphism positive treatment-resistant depression: prevalence and treatment recommendations. Neuropsychiatry. 2016, 6:43-6.","journal-title":"Neuropsychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/346208-prolonged-serotonergic-symptoms-in-a-pediatric-patient-suspected-interaction-between-prescription-medications-and-kava-supplement","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:40:39Z","timestamp":1747064439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/346208-prolonged-serotonergic-symptoms-in-a-pediatric-patient-suspected-interaction-between-prescription-medications-and-kava-supplement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.83966","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}